ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 058

Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis

Cal Robinson 1, Rahul Chanchlani 1, Megan Schlorff 1, Francis Lao 1, Tapas Mondal 1, Catherine Demers 1, Elizabeth Darling 1, Sandeep Brar 2, Rulan Parekh 3, Hsien Seow 1, Eric Benchimol 4 and Michelle Batthish1, 1McMaster University, Hamilton, Canada, 2University of California, San Fransisco, 3University of Toronto, Toronto, Canada, 4University of Ottawa, Ottawa, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: administrative databases, Epidemiologic methods, Kawasaki disease, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed world. However, over the past two decades, data on the incidence, patient and disease characteristics for KD among North American children are conflicting. These data are critical for informing healthcare resource planning. The objectives of this study were to: 1) Determine KD incidence between 1995 to 2017 among children in Ontario; 2) Compare characteristics among KD children by era (1995-2001 and 2002-2017) and age group (0-4yr, 5-9yr, 10-18yr); and 3) Determine rates of acute complications and follow-up patterns after discharge.

Methods: We used population-based health administrative data to identify all children (0-18 years) hospitalized and diagnosed with KD in Ontario, Canada between 1995 and 2017. Children with a previous diagnosis of KD were excluded. We determined the annual incidence of KD and assessed trends over time using the Cochran-Armitage test.

Results: We identified 4,346 children diagnosed with KD over 22 years. Median age was 3 years (IQR 1-5) and male-to-female ratio was 1.5. KD incidence was 22.0 cases (0-4yr), 6.1 cases (5-9yr) and 0.6 (10-18yr) per 100,000 person-years. KD incidence increased significantly for all age groups (18.4 to 25.0 for 0-4yr, 4.0 to 7.7 for 5-9yr and 0.7 to 1.1 for 10-18yr; p< 0.001), and for males and females during the study (7.5 to 11.1 for males, p=0.001 and 4.6 to 6.5 for females, p< 0.0001). Ninety-day mortality was ≤ 0.1%. Coronary artery aneurysms (CAA) occurred in 106 children (2.4%) during admission and 151 (3.5%) over 11-year median follow-up. CAA frequency did not change significantly over time (p=0.07). Compared to the 0-4yr group, older children (10-18yr) had longer hospital stay (4.3 vs 3.5 days, p=0.003), more PICU admissions (5.3% vs 2.1%, p=0.01) and greater frequency of CAA (7.4% vs. 3.4%, p=0.007). 3,970 (91.3%) and 2,576 (59.3%) children had echocardiogram testing and cardiology follow-up, respectively, by 1 year.

Conclusion: The incidence of KD has increased significantly over the past two decades in Ontario, Canada. Children 10-18 years had worse short-term outcomes, highlighting the importance of early diagnosis and treatment. Future research will evaluate the healthcare resource implications of the rising incidence of KD in order to better plan for the provision of high-quality healthcare to these patients.

Figure 1: Incidence of Kawasaki disease among children in Ontario from 1995_2017.

Table 1: Baseline characteristics, by age at index admission.

Table 2: Patient outcomes, by age at index admission.


Disclosure: C. Robinson, None; R. Chanchlani, None; M. Schlorff, None; F. Lao, None; T. Mondal, None; C. Demers, None; E. Darling, None; S. Brar, None; R. Parekh, None; H. Seow, None; E. Benchimol, None; M. Batthish, Abbvie, 1.

To cite this abstract in AMA style:

Robinson C, Chanchlani R, Schlorff M, Lao F, Mondal T, Demers C, Darling E, Brar S, Parekh R, Seow H, Benchimol E, Batthish M. Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/kawasaki-disease-in-ontario-children-from-1995-2017-a-population-based-descriptive-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kawasaki-disease-in-ontario-children-from-1995-2017-a-population-based-descriptive-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology